Affordable Access

Publisher Website

Disease-free survival as an end-point in the treatment of solid tumours – Perspectives from clinical trials and clinical practice

Authors
Journal
European Journal of Cancer
0959-8049
Publisher
Elsevier
Volume
50
Issue
13
Identifiers
DOI: 10.1016/j.ejca.2014.05.016
Keywords
  • Clinical Trials
  • Patient Perspectives
  • Disease-Free Survival
  • Drug Approval
  • Solid Tumours
Disciplines
  • Design

Abstract

Abstract Disease-free survival (DFS) is an end-point for an increasing number of clinical trials in adjuvant and curative intent cancer treatment informing both regulatory bodies and clinical practice. DFS is seen both as a surrogate end-point and as an end-point in itself in clinical trials. Understanding the history of DFS, and some of the assumptions, limitations, and vulnerabilities for studies designed with this primary end-point are required. This commentary reviews recent drug approvals for anti-cancer agents in solid tumours in the adjuvant and curative settings, and considers the meaning of DFS from the perspectives of clinical trials and clinical practice.

There are no comments yet on this publication. Be the first to share your thoughts.